Genvor Inc
Close on Oct 19, 2026
- Market cap
- $22.19M
- P/E (TTM)
- –
- Dividend yield
- –
About Genvor
Agricultural Production-Crops, SIC 0100
Genvor Incorporated is an agricultural biotechnology company that develops peptide technologies to address challenges in crop protection, plant performance, and animal health. Utilizing an artificial intelligence platform called the BioCypher Algorithm, the company designs bioactive peptides, including antimicrobial peptides to combat bacterial, fungal, and viral plant pathogens, as well as nutritionally enhanced and crop-enhancing peptides to improve nutrient uptake and stress resilience. Genvor focuses on agricultural applications such as transgenic seed traits for major crops like corn, soybeans, and cotton, alongside topical foliar biopesticide sprays. It also explores animal nutrition applications to enhance feed efficiency in poultry, swine, and aquaculture. Its target customers and commercial partners include agricultural organizations and growers across conventional and organic markets.
The company operates primarily through research, development, and strategic partnerships, with patent filings extending internationally to Canada, Mexico, and China. Genvor maintains its principal executive offices and corporate headquarters in Henderson, Nevada.
Summary of the business section of Genvor's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Genvor Inc
- Founded
- 2018
- Headquarters
- Henderson, NV
- Address
- 1550 W Horizon Ridge Pkwy, Ste R #3040 89012
- Phone
- (715) 903-6473
- Website
- otcmarkets.com
- Employees
- 2, Sep 30, 2025
- Industry
- Agricultural Production-Crops
- Incorporated in
- Nevada
- Fiscal year ends
- September 30
- Auditor
- Novogradac & Company LLP, Plantation, Florida
Stock & identifiers
- Ticker
- GNVR
- Exchange
- OTC
- Shares outstanding
- 36M, Aug 14, 2026
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1792941
- EIN
- 83-2054746
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Chad Lee Pawlak Sr. | Chief Executive Officer, Director | 7,000,000 |
| Jessee M. Jaynes | Chief Research Officer, Director | 524,000 |
| Donald A. Kalkofen | Chief Financial Officer | – |
| Clayton Clopton Yates | Director | 400,000 |
Employees
Headcount reported in annual reports
“As of September 30, 2025, we had two full-time employees and two scientific employee advisors.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 13, 2025 | Late filing | Notification of late filing |
| May 12, 2025 | Late filing | Notification of late filing |
| Feb 18, 2025 | Late filing | Notification of late filing |
| Jan 31, 2025 | Late filing | Notification of late filing |
| Aug 15, 2024 | Late filing | Notification of late filing |
| Mar 21, 2024 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jan 2, 2024 | Late filing | Notification of late filing |
| Jun 15, 2022 | Name change | Name changed from Allure Worldwide, Inc. to Genvor Inc |
| Jun 9, 2022 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Feb 1, 2021 | Auditor change | Change in certifying accountant (8-K Item 4.01) |